Business
Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities
Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities Canada...
About this update from Oncolytics Biotech Inc.
[{"type":"text","content":"\n\n\n\n Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities\n \n\n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n\n\n\n\n\n Canada NewsWire\n \n\n\n\n\n\n Equity Insider\n \n\n\n News Commentary\n \n\n\n\n\n Issued on behalf of Oncolytics Biotech Inc.\n \n\n\n\n\n\n VANCOUVER. BC\n \n\n ,\n \n\n July 16, 2025\n \n\n /CNW/ -- As lawmakers weigh potential cuts to\n \n scientific research funding\n \n , the outlook for developing cancer cures faces growing uncertainty. The situation is further complicated by\n \n renewed regulatory scrutiny\n \n of mRNA vaccines at both federal and state levels, casting a shadow over ongoing cancer research efforts. Meanwhile, the incidence of cancers—especially\n \n gastrointestinal and colorectal cancers\n \n among younger populations—is on the rise, heightening the need for new therapeutic approaches. In response, a new generation of biotech companies is stepping forward with promising clinical milestones on the horizon, including\n \n Oncolytics Biotech Inc.\n \n (NASDAQ: ONCY) (TSX: ONC),\n \n Zai Lab Limited\n \n (NASDAQ: ZLAB),\n \n GeoVax Labs, Inc.\n \n (NASDAQ: GOVX),\n \n OS Therapies\n \n (NYSE-American: OSTX), and\n \n SELLAS Life Sciences Group, Inc.\n \n (NASDAQ: SLS).\n \n\n\n\n\n\n\n\n\n Industry forecasts suggest the global oncology drug market could climb past\n \n\n US$900 billion\n \n by 2034\n \n . Within that,\n \n next-generation cancer treatments\n \n —powered by advances in personalized and precision medicine—are expected to reach\n \n US$175.2 billion\n \n , according to\n \n Precedence Research\n \n , growing at a compound annual rate of 7.35%.\n \n\n\n Oncolytics Biotech Inc.\n \n (NASDAQ: ONCY) (TSX: ONC) just rolled out an expanded translational data review package that tightens the scientific case for pelareorep, its intravenously delivered oncolytic virus.\n \n\n Fresh analyses from the GOBLET gastrointestinal‑cancer study and the AWARE‑1 breast‑cancer study shows pelareorep actively replicating inside tumors, switching on interferon signal...